Mitera Biosciences is developing a therapeutic drug candidate that enhances the number of circulating Regulatory T cells (Tregs) to address the deficiency in transplant recipients and autoimmune disease patients. This approach aims to provide a safer alternative to traditional immunosuppressive therapies, reducing the toxicity associated with current treatments like calcineurin inhibitors.
Funding
$700K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Transplant recipients and individuals with autoimmune diseases often experience a deficiency in Regulatory T cells (Tregs), leading to immune system imbalances. Current standard-of-care treatments, such as calcineurin inhibitors, can have significant toxicities and long-term adverse effects, including neurologic and kidney injury. Intolerance to these medications can lead to non-adherence and, in the case of transplant recipients, organ rejection and a return to dialysis.
Solution
Mitera Biosciences is developing an investigational therapeutic drug candidate designed to enhance the number of circulating Tregs, addressing the underlying deficiency in transplant and autoimmune disease patients. This approach leverages a novel biological pathway of the human innate immune system to boost Treg production, potentially alleviating the detrimental effects of an overactive immune system. By increasing the number of Tregs, the therapeutic aims to provide a safer and more effective alternative to traditional immunosuppressive therapies, reducing the risk of toxicity and improving long-term outcomes for patients. If successful in clinical studies, this therapeutic could offer a more tolerable treatment option without the adverse effects associated with current immunosuppressant drugs.
Target Audience
The primary target audience includes transplant recipients and individuals suffering from autoimmune diseases who require safer and more effective alternatives to traditional immunosuppressive therapies.
Features
- Focuses on enhancing the number of circulating Regulatory T cells (Tregs) to restore immune balance.
- Targets a novel biological pathway within the human innate immune system to stimulate Treg production.
- Aims to provide a safer alternative to calcineurin inhibitors and other traditional immunosuppressants.
- Designed to reduce the risk of neurologic and kidney injury associated with current treatments.
- Intended to improve long-term outcomes for transplant recipients and autoimmune disease patients.